Afrezza® In Pediatric Patients

Afrezza® In Pediatric Patients

Contact

 If you are interested in participating in the study or want to learn more, please contact: Contact us
This study is no longer recruiting.

Description

The purpose of this research study is to test an investigationaldrug Afrezza (inhaled insulin) in children and adolescents with T1DM between 4and 17 years of age. Afrezza is a rapid acting inhaled insulin, which wasapproved by Food and Drug Administration (FDA) for the treatment of diabetes inadults. Multiple doses of inhaled insulin will be evaluated over an approximate4-week period.

Who can participate? Males or females between 4 and 17 years oldin good general health, diagnosed with Type 1 Diabetes Mellitus and usinginsulin daily for at least 1 year.

Study procedures you can expect during the study: Interviewsabout your health, Physical examination, Blood and urine samples collection fortesting, Lung function test, Electrocardiogram, Afrezza administration, SubjectDiary.

If interested: Please email diabetesresearch@email.chop.edu orcall 267-426-3909.

Eligibility and criteria
IRB Number:
15-012292
Eligible age range:
4 years - 17 years
Clinical trial phase:
N/A
Official title:
Open-label, Single-Arm, Multiple-Dose Safety, Titration, And Pharmacokinetic Study Of AFREZZA In Pediatric Subjects Ages 4 to 17 Years With Type 1 Diabetes Mellitus
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.